Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings

Pfizer's upcoming Q2 earnings report is anticipated to reveal a mixed performance across its non-oncology drug portfolio. The Primary Care segment faces headwinds from IRA pricing pressure on Eliquis and declining international sales for Prevnar, alongside expected drops for Paxlovid and Abrysvo. However, growth is projected for Nurtec, and Vyndaqel is expected to remain strong in Specialty Care, while the Q1 rebound in Comirnaty sales offers a potential upside. Despite a recent stock decline, Pfizer's valuation appears attractive relative to the industry, making the specifics of these segment performances critical for investor assessment of the company's near-term outlook.

Analysis

Pfizer's upcoming second-quarter results are poised to show a divergent performance within its non-oncology segments, which face significant crosscurrents. The Primary Care division is expected to experience headwinds, with revenues from the Bristol-Myers partnered drug Eliquis likely declining due to pricing pressures from the Inflation Reduction Act (IRA) that are anticipated to offset higher demand. Further pressure comes from expected declines in international sales for the Prevnar vaccine, lower demand for the COVID-19 antiviral Paxlovid, and continued weak uptake of the RSV vaccine Abrysvo. Conversely, there are pockets of strength, including anticipated growth from Nurtec and continued strong demand for Vyndaqel in the Specialty Care unit. The trajectory for the COVID-19 vaccine Comirnaty remains a key variable after its Q1 revenue rebound. Despite these operational challenges and a 1.8% year-to-date stock decline, Pfizer's valuation appears compelling, trading at a forward P/E of 8.20, which is substantially below its 5-year mean of 10.85 and the industry average of 14.60. However, this is tempered by minor downward revisions to 2025 and 2026 consensus earnings estimates over the past 60 days.

Key Decisions for Investors

• Investors should scrutinize the upcoming August 5th earnings release for specific sales figures on key products like Eliquis and Paxlovid to quantify the real-world impact of IRA pricing and post-pandemic demand shifts.
• The core consideration is whether Pfizer's attractive valuation, with a forward P/E of 8.20, adequately compensates for the significant fundamental headwinds affecting its major Primary Care franchises.
• Pay close attention to management's updated guidance, as commentary on the performance of the newly integrated Seagen oncology assets and the sales outlook for Comirnaty will be critical to gauge potential offsets to the reported weaknesses.